VISENSIA
OBS MEDICAL • Cardiovascular • 07/17/2008
Device Purpose
The Visensia® system is a software accessory that enhances patient monitoring by employing advanced signal processing to integrate multiple vital signs (heart rate, respiratory rate, temperature, oxygen saturation, and blood pressure) into a single 'Visensia® Index.' This index, derived from a model based on historical clinical data, serves as a quantitative measure of a non-paediatric high dependency patient's deviation from physiological normality, providing clinicians with an alert when significant changes occur.
Summary
Visensia® is a software accessory designed for use with standard multi-parameter patient monitors or clinical information systems, operating on a personal computer. Its primary purpose is to assist healthcare professionals in monitoring non-paediatric high dependency care patients by consolidating multiple physiological signals into a single, easily interpretable metric. The system accepts inputs such as heart rate, respiratory rate, temperature, blood pressure, and oxygen saturation. Through advanced signal processing, Visensia® calculates the 'Visensia® Index,' which is a weighted average of these vital signs. This index represents the patient's current physiological condition relative to a baseline of normality, providing a continuous assessment of their status. The scientific basis of the Visensia® Index lies in its ability to fuse data from either four or five vital signs, with the model for determining 'normality' and deviations derived from historical clinical data. The Visensia® with Alert feature acts as an adjunctive decision support tool, alerting clinicians when the Visensia® Index surpasses a predefined threshold. This indicates a significant change in the patient's physiological status that warrants attention, but it does not replace traditional vital sign monitoring or alarms. Clinical testing data has demonstrated the effectiveness of the Visensia® system and its alert function, showing a correlation between the activation of alerts and actual patient deterioration. The system is designed for use on standard PC hardware with no direct patient contact, posing minimal electrical safety risk.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How is the 'weighted average' for the Visensia® Index calculated, and what is the specific contribution or weighting of each of the four or five vital signs?; What specific 'historical clinical data' was used to establish the model of 'normality' for the Visensia® Index, and how diverse was this dataset in terms of patient populations and conditions?; Can the default threshold for the Visensia® Alert be customized by clinicians based on specific patient populations or individual patient needs, and if so, what guidance is provided for such customization?; What were the specific endpoints and outcomes measured in the clinical testing that demonstrated the 'effectiveness of Visensia®' and the correlation between its alerting function and 'patient deterioration'?; How does the 'advanced signal processing' algorithm account for potential artifacts or noise in the input physiological signals from various multi-parameter monitors?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class C (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of SBOM, ML-BOM, HBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Not detected in AI-generated device summary: SaaSBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly